Physician profile
Jennifer K Eckerman
NPI 1790876381
$6,416.28
in general payments reported to CMS, 2019-2025
36 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $873 · 2022: $1,190 · 2023: $1,109 · 2024: $2,136 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412 · Travel and Lodging: $801 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,411.88 |
| Travel and Lodging | $801.20 |
| Education | $139.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,257.61 | 2021-2025 | Xtandi, Myrbetriq |
| Medtronic, INC. | $1,052.10 | 2024 | Interstim |
| Sumitomo Pharma America, INC. | $591.61 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $358.54 | 2021-2025 | Erleada |
| Abbvie INC. | $330.68 | 2021-2025 | |
| Pfizer INC. | $319.46 | 2021-2025 | |
| Procept Biorobotics Corporation | $274.26 | 2023-2025 | Aquabeam Robotic System |
| Urovant Sciences INC | $219.30 | 2022 | |
| Urogen Pharma, INC. | $183.20 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $159.85 | 2021-2024 | Myrisk, Prolaris |
| Axonics, INC. | $155.81 | 2022-2024 | Axonics |
| Progenics Pharmaceuticals, INC. | $148.81 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $144.69 | 2022-2023 | Lynparza |
| Tolmar Pharmaceuticals, INC. | $120.88 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $110.17 | 2021-2024 | Xiaflex, Aveed |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $102.47 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Bluewind Medical | $99.21 | 2025 | Revi |
| Coloplast Corp | $78.22 | 2022-2024 | Altis |
| Merck Sharp & Dohme LLC | $74.94 | 2021-2024 | Lynparza |
| Photocure INC | $73.08 | 2023 | Cysview |
| Foundation Medicine, INC. | $64.88 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $61.41 | 2024-2025 | Adstiladrin |
| Sun Pharmaceutical Industries INC. | $59.37 | 2022-2024 | |
| Accord Healthcare, INC. | $51.80 | 2024 | |
| Janssen Scientific Affairs, LLC | $48.00 | 2022-2023 | Balversa, Erleada |
| Dendreon Pharmaceuticals LLC | $41.61 | 2021-2024 | Provenge |
| Allergan, INC. | $40.53 | 2021-2022 | |
| Smith+Nephew, INC. | $34.10 | 2023 | Stravix Pl |
| Tolmar, INC. | $24.59 | 2023 | |
| Olympus America INC. | $22.92 | 2025 | Itind System |
| Blue Earth Diagnostics | $22.60 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $19.73 | 2025 | |
| Boston Scientific Corporation | $19.07 | 2025 | Ams 700 |
| Verity Pharmaceuticals INC. | $18.30 | 2025 | Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $16.52 | 2022 | |
| Baudax Bio INC. | $15.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Eckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.